Filing Flows › Comparisons › ALT vs ONCO
Altimmune vs Onconetix: ALT and ONCO compared
Altimmune is the larger company: $26K of revenue in its latest quarter (Q4 2025) against $17K for Onconetix (Q2 2026). Altimmune is growing faster (+420% against -84% a year earlier).
Where the money goes: ALT and ONCO
Altimmune (ALT) · Q4 2025
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
Onconetix (ONCO) · Q2 2026
Onconetix, Q2 2026: revenue $17K (-84% year over year), net loss $2.9M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Altimmune (ALT) | Onconetix (ONCO) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $26K | $17K |
| Revenue growth, Y/Y | +420% | -84% |
| Operating margin | n/m | n/m |
| Net earnings | −$27.4M | −$2.9M |
| Operating cash flow | −$19.4M | −$1.9M |
Questions
Which is bigger, Altimmune or Onconetix?
Altimmune is the larger company: $26K of revenue in its latest quarter (Q4 2025) against $17K for Onconetix (Q2 2026).
Is Altimmune or Onconetix growing faster?
Altimmune is growing faster (+420% against -84% a year earlier).
More: Altimmune earnings · how Altimmune makes money · Onconetix earnings · how Onconetix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 6, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.